A2_60d_Comments_2006

Attachment 2

CDC Responses to comments received, 2006

OMB No. 0920-05AJ

Attachment 7

Comments and CDC Response to the 2006 Federal Register Notice

C enters for Disease Control

and Prevention (CDC)

Atlanta GA 30333

March 2, 2007

B. Sachau

15 Elm St.

Florham Park

New Jersey 07932

Dear B. Sachau,

I am responding to your comment on the December 14, 2006 issue of the Federal Register, Volume 71, No. 240, page 75256 on the proposed project entitled National Surveillance for Severe Adverse Events (Hospitalization or Death) Associated with Treatment of Latent Tuberculosis Infection.

Our office, Division of Tuberculosis Elimination (DTBE) at the Centers for Disease Control and Prevention (CDC), is collaborating with agencies responsible for immigration screening such as the Division of Global Migration and Quarantine, CDC and the Department of Immigration and Customs Enforcement. We are developing better TB screening and monitoring methods for persons seeking to enter the United States. In addition, we are collaborating with the Food and Drug Administration, the agency responsible for regulating drugs such as those used to treat TB, in monitoring severe adverse events due to treatment for TB.

Thank you for your interest and concern about immigration and TB and we hope this letter alleviates your concern.

Sincerely,

Lilia Manangan, RN, MPH

DTBE, CDC, Mailstop E-10

National Center for HIV, STD, and TB Prevention

Coordinating Center for Infectious Diseases

1600 Clifton Road, Atlanta, GA 30333